Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.

Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L.

JAMA. 2019 Aug 27;322(8):746-755. doi: 10.1001/jama.2019.11642.

PMID:
31454045
2.

Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites.

Bai A, Bielawska A, Rahmaniyan M, Kraveka JM, Bielawski J, Hannun YA.

Bioorg Med Chem. 2018 Dec 15;26(23-24):6067-6075. doi: 10.1016/j.bmc.2018.11.012. Epub 2018 Nov 10.

PMID:
30448190
3.

Maintenance DFMO Increases Survival in High Risk Neuroblastoma.

Sholler GLS, Ferguson W, Bergendahl G, Bond JP, Neville K, Eslin D, Brown V, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Parikh NS, Eshun F, Zage P, Rawwas J, Sencer S, Pankiewicz D, Quinn M, Rich M, Junewick J, Kraveka JM.

Sci Rep. 2018 Sep 27;8(1):14445. doi: 10.1038/s41598-018-32659-w.

4.

Updates in Diagnosis, Management, and Treatment of Neuroblastoma.

Swift CC, Eklund MJ, Kraveka JM, Alazraki AL.

Radiographics. 2018 Mar-Apr;38(2):566-580. doi: 10.1148/rg.2018170132. Review.

PMID:
29528815
5.

Fumonisin B1 Inhibits Endoplasmic Reticulum Stress Associated-apoptosis After FoscanPDT Combined with C6-Pyridinium Ceramide or Fenretinide.

Boppana NB, Kraveka JM, Rahmaniyan M, Li LI, Bielawska A, Bielawski J, Pierce JS, Delor JS, Zhang K, Korbelik M, Separovic D.

Anticancer Res. 2017 Feb;37(2):455-463.

6.

The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.

Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C.

Mol Cancer Ther. 2015 Dec;14(12):2744-52. doi: 10.1158/1535-7163.MCT-15-0279. Epub 2015 Oct 22.

7.

A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.

Saulnier Sholler GL, Gerner EW, Bergendahl G, MacArthur RB, VanderWerff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender L, Higgins T, Kawakita M, Hiramatsu K, Moriya SS, Bachmann AS.

PLoS One. 2015 May 27;10(5):e0127246. doi: 10.1371/journal.pone.0127246. eCollection 2015.

8.

Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group.

Alexander S, Kraveka JM, Weitzman S, Lowe E, Smith L, Lynch JC, Chang M, Kinney MC, Perkins SL, Laver J, Gross TG, Weinstein H.

Pediatr Blood Cancer. 2014 Dec;61(12):2236-42. doi: 10.1002/pbc.25187. Epub 2014 Aug 23.

9.

Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation.

Separovic D, Breen P, Boppana NB, Van Buren E, Joseph N, Kraveka JM, Rahmaniyan M, Li L, Gudz TI, Bielawska A, Bai A, Bielawski J, Pierce JS, Korbelik M.

Int J Oncol. 2013 Dec;43(6):2064-72. doi: 10.3892/ijo.2013.2132. Epub 2013 Oct 9.

10.

Neuroblastoma in an adult: case presentation and literature review.

Smith L, Minter S, O'Brien P, Kraveka JM, Medina AM, Lazarchick J.

Ann Clin Lab Sci. 2013 Winter;43(1):81-4. Review.

PMID:
23462610
11.

Dihydroceramide desaturase knockdown impacts sphingolipids and apoptosis after photodamage in human head and neck squamous carcinoma cells.

Breen P, Joseph N, Thompson K, Kraveka JM, Gudz TI, Li L, Rahmaniyan M, Bielawski J, Pierce JS, VAN Buren E, Bhatti G, Separovic D.

Anticancer Res. 2013 Jan;33(1):77-84.

12.

Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction.

Meyers-Needham M, Lewis JA, Gencer S, Sentelle RD, Saddoughi SA, Clarke CJ, Hannun YA, Norell H, da Palma TM, Nishimura M, Kraveka JM, Khavandgar Z, Murshed M, Cevik MO, Ogretmen B.

Mol Cancer Ther. 2012 May;11(5):1092-102. doi: 10.1158/1535-7163.MCT-11-0705. Epub 2012 Mar 27.

13.

Cell density-dependent reduction of dihydroceramide desaturase activity in neuroblastoma cells.

Spassieva SD, Rahmaniyan M, Bielawski J, Clarke CJ, Kraveka JM, Obeid LM.

J Lipid Res. 2012 May;53(5):918-28. doi: 10.1194/jlr.M019075. Epub 2012 Feb 29.

14.

Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide.

Rahmaniyan M, Curley RW Jr, Obeid LM, Hannun YA, Kraveka JM.

J Biol Chem. 2011 Jul 15;286(28):24754-64. doi: 10.1074/jbc.M111.250779. Epub 2011 May 4.

15.

Dihydroceramide desaturase activity is modulated by oxidative stress.

Idkowiak-Baldys J, Apraiz A, Li L, Rahmaniyan M, Clarke CJ, Kraveka JM, Asumendi A, Hannun YA.

Biochem J. 2010 Mar 29;427(2):265-74. doi: 10.1042/BJ20091589.

16.

Ceramide generated by sphingomyelin hydrolysis and the salvage pathway is involved in hypoxia/reoxygenation-induced Bax redistribution to mitochondria in NT-2 cells.

Jin J, Hou Q, Mullen TD, Zeidan YH, Bielawski J, Kraveka JM, Bielawska A, Obeid LM, Hannun YA, Hsu YT.

J Biol Chem. 2008 Sep 26;283(39):26509-17. doi: 10.1074/jbc.M801597200. Epub 2008 Aug 1.

17.

Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells.

Kraveka JM, Li L, Szulc ZM, Bielawski J, Ogretmen B, Hannun YA, Obeid LM, Bielawska A.

J Biol Chem. 2007 Jun 8;282(23):16718-28. Epub 2007 Feb 5.

18.
19.

CD19 negative precursor B acute lymphoblastic leukemia presenting with hypercalcemia.

Sultan I, Kraveka JM, Lazarchick J.

Pediatr Blood Cancer. 2004 Jul;43(1):66-9.

PMID:
15170892
20.
21.

Ceramide regulation of apoptosis versus differentiation: a walk on a fine line. Lessons from neurobiology.

Luberto C, Kraveka JM, Hannun YA.

Neurochem Res. 2002 Aug;27(7-8):609-17. Review.

PMID:
12374196
22.

Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line.

Ogretmen B, Kraveka JM, Schady D, Usta J, Hannun YA, Obeid LM.

J Biol Chem. 2001 Aug 31;276(35):32506-14. Epub 2001 Jul 5.

23.

Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells.

Ogretmen B, Schady D, Usta J, Wood R, Kraveka JM, Luberto C, Birbes H, Hannun YA, Obeid LM.

J Biol Chem. 2001 Jul 6;276(27):24901-10. Epub 2001 May 2.

24.

Immunoprecipitation of human telomerase reverse transcriptase with telomerase activity.

Kraveka JM, Schady D, Obeid LM, Ogretmen B.

Anal Biochem. 2001 Apr 1;291(1):166-9. No abstract available.

PMID:
11262172

Supplemental Content

Loading ...
Support Center